Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03162614 · ClinicalTrials.gov registry record · Phase 2

Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

A Phase 2 study of Malaria, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
154
Enrollment target
1
Study location

NCT03162614 is a Phase 2 study of Malaria that has completed, run by GlaxoSmithKline. The registered enrollment target is 154 participants, below the 252-participant average among 27 other Malaria trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03162614, a Phase 2 study of Malaria, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
154 participants
Enrollment target
1
Study location

Study Summary

This study is designed to evaluate efficacy, immunogenicity and safety of various dose schedules of GSK Biologicals' candidate malaria vaccines RTS,S/AS01B (adult formulation) and RTS,S/AS01E (pediatric formulation) in healthy malaria-naïve subjects aged 18-55 years. The purpose of this study is to investigate whether changes in dosing schedule are associated with increased or equivalent protection, and to evaluate the immune mechanisms associated with vaccine efficacy under varying dosing schedules.

Conditions Studied

Interventions

  • BIOLOGICAL RTS,S/AS01E
  • BIOLOGICAL RTS,S/AS01B
  • PROCEDURE Sporozoite-infected mosquitoes challenge.

Study Locations (1)

Maryland

  • GSK Investigational Site - Silver Spring

Trial Details

FieldValue
Enrollment Target 154 participants
Start Date 2017-05-24
Est. Completion 2018-09-24
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

What the Registry Record Tells You About NCT03162614

The ClinicalTrials.gov registry entry for NCT03162614 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 252-participant average among 27 other Malaria trials with a reported enrollment target (39% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Malaria appearing as the primary indexed condition, and to 3 interventions - of which RTS,S/AS01E is the first listed.

NCT03162614 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT03162614 about?

NCT03162614 is a clinical study titled "Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults". This study is designed to evaluate efficacy, immunogenicity and safety of various dose schedules of GSK Biologicals' candidate malaria vaccines RTS,S/AS01B (adult formulation) and RTS,S/AS01E (pediatric formulation) in healthy malaria-naïve subjects aged 18-55 years. The purpose of this study is to ...

What is the current status of trial NCT03162614?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2017-05-24. Estimated completion is 2018-09-24.

What conditions does trial NCT03162614 study?

This clinical trial studies the following conditions: Malaria.

What interventions are being tested in trial NCT03162614?

The interventions under investigation include: RTS,S/AS01E (BIOLOGICAL), RTS,S/AS01B (BIOLOGICAL), Sporozoite-infected mosquitoes challenge. (PROCEDURE).

Who is sponsoring clinical trial NCT03162614?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03162614 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malaria

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.